Список проголосовавших за комментарий " Notable movers of interest: NFLX +2.1% on upgrade from UBS<p>The following are some of today's most notable movers of interest, categorized by market capitalization (large cap over $10 billion and mid cap between $2-10 billion) and ranked by % change (all stocks over 100K average daily volume).</p><p><strong>Large Cap Gainers</strong></p><ul><li><strong>NFLX</strong> (142.12 +2.14%): Upgraded to Buy from Neutral at UBS.</li><li><strong>QVCA</strong> (19.07 +1.11%): Barrons profile's positive view on the co over the weekend.</li></ul><p><strong>Large Cap Losers</strong></p><ul><li><strong>TSN</strong> (61.23 -3.73%): WSJ discusses that bird flu was found in chicken farm linked to Tyson Foods.</li><li><strong>ALB</strong> (101.45 -3.17%): Downgraded to Neutral from Buy at Citigroup.</li><li><strong>DAL</strong> (48.72 -2.81%): Cuts Q1 PRASM guidance to flat from +0-2%; operating margin to 10-11% from 11-13% (<strong>AAL</strong>, <strong>UAL</strong>, <strong>LUV</strong>...).</li></ul><p><strong>Mid Cap Gainers</strong></p><ul><li><strong>KITE</strong> (74.28 +2.41%): BC Capital Mkts raises their tgt to $95 from $85.</li><li><strong>XRX</strong> (7.5 +1.9%): Barron's profiles positive view on Xerox.</li><li><strong>AA</strong> (36.9 +1.43%): Upgraded to Buy from Neutral at Goldman.</li></ul><p><strong>Mid Cap Losers</strong></p><ul><li><strong>IONS</strong> (50.53 -7.63%): Shares fall despite co and Akcea Therapeutics announcing the pivotal Phase 3 Approach study of Volanesorsen met its primary endpoint of reducing triglyceride levels in patients with familial chylomicronemia syndrome.</li><li><strong>CSRA</strong> (28.58 -4.54%): Downgraded to Market Perform from Outperform at Cowen.</li><li><strong>WSM</strong> (49.13 -2.4%): Wedbush lowers their tgt to $48 from $53.</li></ul>"